News | June 04, 2012

SentreHeart Secures $26 Million to Commercialize Lariat Suture Delivery Device

June 4, 2012 — SentreHeart Inc., a privately held medical device company, announced that it has recently completed a $26 million Series C financing led by Vivo Ventures, with participation by its existing investors US Venture Partners and Prospect Ventures.

“We are delighted to have the continuing financial and strategic support of these top investment firms," said Paul Buckman, president and CEO of SentreHeart. "The Lariat suture delivery device has the potential to transform certain open surgical procedures traditionally performed in the operating room into more cost-effective procedures that can be performed in the catheterization lab, where only a small piece of suture is left behind. We believe it may have application in more than 2.5 million procedures annually, which represents a $1.6 billion market opportunity worldwide.”

The Lariat device facilitates suture placement and knot tying for use in surgical applications where soft tissues are being approximated and/or ligated using a pre-tied polyester suture.

Along with the new funding, SentreHeart also announced that Chen Yu, managing partner from Vivo Ventures, would join the board of directors. Yu is a board member in many life science companies and received his M.D. and M.B.A. from Stanford University and graduated magna cum laude with a B.A. in biology from Harvard University.

“This financing, along with recent additions to our leadership team of several veteran medical device executives, enables us to expand upon our early commercial success,” said Buckman. “We have seen that our technology is being rapidly adopted by physicians around the world and we now look to support and continue this steady growth. Our ongoing clinical and commercial successes confirm the market need for soft tissue closure without the expense and morbidities associated with traditional open surgeries.”

The Lariat suture delivery device is for remote delivery of a pre-tied suture loop. Innovation in catheter and suture delivery technology enables physicians to remotely deliver a 40 mm pre-tied suture loop for immediate and complete soft tissue closure through access as small as 4.3 mm and with no metal, clips or fabrics left behind. Regulatory clearance for soft tissue ligation and approximation has been received in the United States, Europe and Canada.

For more information:

Related Content

Transplanting Pig Hearts Into Humans One Step Closer. A pig heart, shown here, is very similar in size and anatomy to a human heart. For this reason, pigs are used extensively in pre-clinical animal testing for new implantable cardiovascular devices. If pig hearts could be used for human transplantation, it would greatly alleviate shortages of donor human hearts.

A pig heart, shown here, is very similar in size and anatomy to a human heart. For this reason, pigs are used extensively in pre-clinical animal testing for new implantable cardiovascular devices. If pig hearts could be used for human transplantation, it would greatly alleviate shortages of donor human hearts.

News | Cardiovascular Surgery | December 11, 2018
The scientific journal Nature recently published an article from Munich University Hospital which describes the long-...
Bilateral Artery Use Does Not Improve 10-Year CABG Outcomes
News | Cardiovascular Surgery | September 06, 2018
While it is firmly established that the use of one internal thoracic artery can improve life expectancy in coronary...
Mandatory Public Coronary Artery Bypass Grafting Reporting Associated With Better Patient Outcomes
News | Cardiovascular Surgery | April 30, 2018
Mandatory public reporting of coronary artery bypass grafting (CABG) results in Massachusetts was associated with...
Gecko Biomedical Receives CE Mark Approval for Setalum Sealant
News | Cardiovascular Surgery | September 19, 2017
Gecko Biomedical announced it has received CE Mark approval for its Setalum Sealant, allowing the company to market its...
ClearFlow Inc. Announces Positive U.S. Clinical Trial Results
News | Cardiovascular Surgery | September 08, 2017
September 8, 2017 — ClearFlow Inc.
Videos | Cardiovascular Surgery | July 19, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Intensive Glycemic Control Program Produces Significant Per-Patient Cost Savings for CABG Surgery
News | Cardiovascular Surgery | May 25, 2017
A new study from Emory University observed a near-20 percent reduction in perioperative complications, a 1.2-day...
Risk of Heart Transplant Rejection Reduced by Desensitizing Patient Antibodies
News | Cardiovascular Surgery | May 23, 2017
The risk of heart transplant rejection can be reduced by desensitizing patient antibodies, according to research...
Scientists Show How Cells React to Injury From Open-Heart Surgery
News | Cardiovascular Surgery | May 04, 2017
Cedars-Sinai Heart Institute investigators have learned how cardiac muscle cells react to a certain type of injury that...
Overlay Init